{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

A survey to assess the usage pattern of Safinamide in the management of Parkinson’s disease in India

Survey Questionnaire Form
Doctor’s details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire

  1. How many patients of Parkinson’s Disease (PD) do you see in a month? *

  2. In your clinical practice, what percentage of PD patients have young onset PD? *

  3. From your clinical experience, mention the stage wise % of PD patients that present to you at diagnosis? *
    4. Stage-1
    %
    Stage-2
    %
    Stage-3
    %
    Stage-4
    %
    Stage-5
    %
  4. Kindly number the below mentioned motor symptoms of PD in order of onset in most of your PD cases. *
    5. Resting tremors
    Bradykinesia
    Rigidity
    Postural reflex disturbance
  5. In your clinical practice, are the patients screened for non-motor symptoms of PD after there is provisional/confirmed diagnosis of PD ? *

  6. Mention most common non-motor symptoms reported by the PD patients, based on your clinical experience. *
    7. A.
    B.
    C.
    D.
    E.
  7. Is there any difference in the non-motor symptoms of PD based on the gender of the patient? *

    8. 7.a. If the answer to the Question 7 is “Yes” then kindly mention the common non-motor symptoms based on the gender based on your clinical practice.

  8. How frequently do you utilize DaTscan or similar imaging techniques for PD diagnosis? *

  9. What is the most significant challenge you face in managing PD patients? *
  10. In your clinical practice, what percentage of PD patients report motor complications after 3-4 years of antiparkinsonian treatment? *

  11. Which is your preferred pharmacological treatment option for patients on Levodopa and experiencing frequent wearing -off episodes ? *

  12. How often do you prescribe safinamide as an adjunct therapy for Parkinson's Disease? *

  13. What percentage of your Parkinson's Disease patients currently take safinamide? *

  14. In what stage of PD do you primarily prescribe safinamide? *

  15. In your experience, how effective is safinamide in reducing motor symptoms of Parkinson's Disease? *

  16. How would you rate the tolerability of safinamide compared to other Parkinson's Disease medications? *

  17. Do you believe safinamide has advantages over other MAO-B inhibitors in treating Parkinson's Disease? *

  18. In your clinical practice, what is the place in therapy of safinamide in management of PD? *
  19. How often do you conduct follow-up visits for stable PD patients on safinamide? *

  20. How do you assess disease progression and treatment response PD patients on Safinamide? *

  21. Based on your clinical experience, knowledge and practice, what are the potential reasons for choosing Safinamide? *
  22. What is your typical starting dose of safinamide? *

  23. In your experience, how effective is safinamide in reducing motor fluctuations and OFF time? *

  24. Have you observed any improvement in non-motor symptoms (e.g., cognitive function, mood) with safinamide treatment? *

  25. Would you recommend safinamide as a first-line therapy for newly diagnosed Parkinson's Disease patients? *

  26. What percentage of your patients report satisfactory compliance with safinamide treatment? *

  27. What is your approach to transitioning patients to safinamide from other PD medications? *
  28. In your opinion, what advantage does Safinamide offer over existing therapies for PD? *
  29. On a scale of 1 to 5 (1 being poor and 5 being excellent). How would you rate your overall satisfaction with safinamide as a treatment option for PD? *
  30. Based on your experience, do you think additional research is needed to better understand safinamide's role in Parkinson's Disease management? *

  31. How do you adjust the treatment plan based on the disease progression? *
  32. In what situations do you consider Surgical interventions (eg. Deep brain stimulation) in PD patients? *